ow dose oral metronomic therapy in recurrent refractory uterine endometrial cancer
- Conditions
- Health Condition 1: C55- Malignant neoplasm of uterus, partunspecified
- Registration Number
- CTRI/2024/07/070458
- Lead Sponsor
- Dr Bhoor Singh
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
1.Histologically confirmed recurrent / refractory high grade endometrial cancer [endometroid/serous/carcinosarcoma/clear cell]
2.One or more prior lines of therapy with at least one platinum based chemotherapeutic regimen, containing carboplatin or cisplatin with platinum free interval of less than 1 year.
3.Written informed consent.
4.ECOG PS 0-2
5.Measurable disease with at least one target lesion which could be used for response evaluation as per RECIST 1.1 criteria
6.Adequate organ function
1.Low grade [grade I/II] endometrial cancer
2.Patient who are eligible for hormonal therapy
3. Patients with recurrent carcinoma endometrium with platinum free interval of more than 1 year
4.Chemotherapy naïve patient [adjuvant/metastatic setting]
5.Patients who are eligible/affordable for immunotherapy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method